Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01159548
Other study ID # 2009-0034B
Secondary ID
Status Terminated
Phase N/A
First received July 7, 2010
Last updated July 26, 2011
Start date July 2010
Est. completion date July 2012

Study information

Verified date July 2011
Source Women's College Hospital
Contact n/a
Is FDA regulated No
Health authority Canada: Women's College Hospital Reserach Ethics Board
Study type Interventional

Clinical Trial Summary

There has been an increase in ambulatory surgical procedures performed across Canada; ambulatory procedures account for almost 70% of all surgeries. Postoperative nausea and vomiting (PONV) and pain are the most frequently reported adverse events by patients prior to discharge after ambulatory surgery. The incidence can be as high as 70 to 80% in high-risk patients.

PONV is a cause of morbidity particularly in gynecological procedures and the incidence of patients experiencing PONV is as high as 58-75%. Apart from delayed recovery, the occurrence of PONV has been linked to gastric aspiration, psychological distress and wound dehiscence. The occurrence of PONV delays patient discharge and further more is a leading cause of unexpected admission after ambulatory anesthesia

Promethazine, is an antiemetic medication that has been widely used over the last 50 years, and although effective at reducing PONV, it tends to cause sedation. In this study, we are trying to determine if a smaller dose of promethazine, in addition to the standard treatment for post-surgical nausea and vomiting, will be more beneficial than the standard treatment on its own.

It is hypothesized that the use of low dose promethazine (3 mg) as part of a multimodal antiemetic regimen will be efficacious in preventing PONV without the sedative effects of promethazine.


Recruitment information / eligibility

Status Terminated
Enrollment 400
Est. completion date July 2012
Est. primary completion date July 2012
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

1. Patient is between 18 - 60 yrs of age

2 Patient's health is graded as class I-III according to the American Society of Anesthesiologists physical status classification.

3. The patient has 2 or more of the following risk factors:

- Female

- Non-smoker

- History of PONV/motion sickness

- Use of post-operative opioids (current surgery)

4. Undergoing ambulatory gynecological laparoscopic procedures of at least 30 minutes duration

Exclusion Criteria:

- preexisting nausea, vomiting or retching, gastric outlet or intestinal obstruction

- clinical evidence of a difficult airway

- obesity (body mass index > 40 kg m-2)

- scheduled to receive propofol for anesthesia maintenance

- current pregnancy

- psychiatric illness

- clinically significant major organic disease

- preoperative QTc interval > 440 ms on electrocardiogram

- known hypersensitivity to promethazine, granisetron, ondansetron or other 5 HT3-receptor antagonists

Study Design

Allocation: Randomized, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms

  • Ambulatory Gynecological Laparoscopic Procedures
  • Postoperative Nausea and Vomiting

Intervention

Drug:
Promethazine

Promethazine


Locations

Country Name City State
Canada Women's College Hospital Toronto Ontario

Sponsors (1)

Lead Sponsor Collaborator
Women's College Hospital

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Absence of emetic episode for 24 h in the postoperative period